The use of intraocular corticosteroids

Expert Opinion on Pharmacotherapy

Volumn 10, Issue 15, 2009, Pages 2511-2525

  Kiernan, Daniel F ^a,b   Mieler, William F ^a,b  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Choroidal neovascularization (CNV); Clinical trials; Cystoid macular edema (CME); Dexamethasone; Diabetic macular edema (DME); Fluocinolone acetonide; Intravitreal implant; Retinal vein occlusion; Triamcinolone acetonide

Indexed keywords

ANTIGLAUCOMA AGENT; APTAMER; BEVACIZUMAB; CORTICOSTEROID; DEXAMETHASONE; FLUOCINOLONE; FLUOCINOLONE ACETONIDE; ILUVEIN; IMMUNOSUPPRESSIVE AGENT; IVATION; KENACORT 40; MEDIDUR; NOVADUR; OZURDEX; PEGAPTANIB; PLACEBO; RANIBIZUMAB; STEROID; TRIAMCINOLONE; TRIAMCINOLONE ACETONIDE; TRIESENCE; UNCLASSIFIED DRUG; VASCULOTROPIN INHIBITOR; VERTEPORFIN;

ABSENCE OF SIDE EFFECTS; ADJUVANT THERAPY; CATARACT; CATARACT EXTRACTION; CHEMOSIS; CHOROID DETACHMENT; CLINICAL TRIAL; CONJUNCTIVAL HEMORRHAGE; CORNEA EDEMA; DIABETIC MACULAR EDEMA; DIABETIC RETINOPATHY; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG INHIBITION; DRUG MEGADOSE; DRUG SAFETY; DRUG SOLUBILITY; EYELID EDEMA; GLAUCOMA; HUMAN; IMPLANT; INJECTION; INTRAOCULAR HYPERTENSION; INTRAOCULAR HYPOTENSION; LASER COAGULATION; LONG TERM CARE; LOW DRUG DOSE; NONHUMAN; OPHTHALMOSCOPY; PEROPERATIVE CARE; PHOTODYNAMIC THERAPY; POSTOPERATIVE COMPLICATION; PROSPECTIVE STUDY; PTOSIS; RETINA; RETINA HEMORRHAGE; RETINA MACULA AGE RELATED DEGENERATION; RETINA MACULA CYSTOID EDEMA; RETINA MACULA EDEMA; RETINA VEIN OCCLUSION; REVIEW; SINGLE DRUG DOSE; SUBRETINAL NEOVASCULARIZATION; SUSPENSION; SUSTAINED DRUG RELEASE; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT OUTCOME; UVEITIS; VISUAL ACUITY; VISUAL IMPAIRMENT; VITREOUS HEMORRHAGE; VITREOUS OPACITY;

ANIMALS; ANTI-INFLAMMATORY AGENTS; CLINICAL TRIALS AS TOPIC; DRUG IMPLANTS; GLUCOCORTICOIDS; HUMANS; INJECTIONS; MACULAR DEGENERATION; RETINAL VEIN OCCLUSION; TRIAMCINOLONE ACETONIDE; UVEITIS; VITREOUS BODY;

EID: 70349504173     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656560903160671     Document Type: Review

References (98)

1. Grossniklaus HE, Ling JX, Wallace TM, et al. Macrophage and retinal pigment epithelium expression of angiogenic cytokines in choroidal neovascularization. Mol Vis 2002;21:119-126
2. Bhutto IA, McLeod DS, Hasegawa T, et al. Pigment epithelium-derived factor (PEDF) and vascular endothelial growth factor (VEGF) in aged human choroids and eyes with age-related macular degeneration. Exp Eye Res 2006;82:99-110 (Pubitemid 43063401)
3. Kreines K, Weinberg IC. The selection of adrenocorticosteroid preparations. Ohio State Med J 1975;71:698,703-706
4. Nauck M, Karakiulakis G, Perruchoud A, et al. Corticosteroids inhibit the expression of the vascular endothelial growth factor gene in human vascular smooth muscle cells. Eur J Pharmacol 1998;341:309-315 (Pubitemid 28131129)
5. Crum R, Szabo S, Folkman J. A new class of steroids inhibits angiogenesis in the presence of heparin or a heparin fragment. Science 1985;230:1375-1378 (Pubitemid 16105166)
6. Duguid IG, Boyd AW, Mandel TE. Adhesion molecules are expressed in the human retina and choroid. Curr Eye Res 1992;11(Suppl):153-159
7. Jaffe GJ, Martin D, Callanan D, et al. Fluocinolone acetonide implant (Retisert) for noninfectious posterior uveitis: thirty-four week results of a multicenter randomized clinical study. Ophthalmol 2006;113:1020-1027 •• Prospective, masked, randomized, multicenter trial of 34-week safety and efficacy results of a 3-year study to evaluate an investigational intravitreal fluocinolone acetonide implant in patients with noninfectious posterior uveitis. The implant significantly reduced uveitis recurrences, improved visual acuity, and decreased the need for adjunctive therapy, although side effects included increased intraocular pressure and cataract progression. (Pubitemid 43795240)
8. Jermak CM, Dellacroce JT, Heffez J, Peyman GA. Triamcinolone acetonide in ocular therapeutics. Surv Ophthalmol 2007;52(5):503-522
9. Andrade RE, Muccioli C, Farah ME, et al. Intravitreal triamcinolone in the treatment of serous retinal detachment in Vogt-Koyanagi-Harada syndrome. Am J Ophthalmol 2004;137:572-574 (Pubitemid 38328658)
10. Francis BA, Chang EL, Haik BG. Particle size and drug interactions of injectable corticosteroids used in ophthalmic practice. Ophthalmology 1996;103:1884-1888
11. Gillies MC, Sutter FK, Simpson JM, et al. Intravitreal triamcinolone for refractory diabetic macular edema: two-year results of a double-masked, placebo-controlled, randomized clinical trial. Ophthalmology 2006;(113):1533-1538
12. Jonas JB, Kamppeter BA, Harder B, et al. Intravitreal triamcinolone acetonide for diabetic macular edema: a prospective, randomized study. J Ocul Pharmacol Ther 2006;22:200-207 (Pubitemid 44051133)
13. Dehghan MH, Ahmadieh H, Ramezani A, et al. A randomized, placebo-controlled clinical trial of intravitreal triamcinolone for refractory diabetic macular edema. Int Ophthalmol 2008;28:7-17 (Pubitemid 351308679)
14. Cardillo JA, Melo LA Jr, Costa RA, et al. Comparison of intravitreal versus posterior sub-Tenon's capsule injection of triamcinolone acetonide for diffuse diabetic macular edema. Ophthalmology 2005;112:1557-1563 (Pubitemid 41725412)
15. Yilmaz T, Weaver CD, Gallagher MJ, et al. Intravitreal triamcinolone acetonide injection for treatment of refractory diabetic macular edema: a systematic review. Ophthalmology 2009;116:902-911 • Review of four randomized clinical trials comparing intravitreal triamcinolone acetonide (IVTA) injection with placebo or no treatment, and two randomized clinical trials comparing IVTA injection with sub-Tenon's triamcinolone acetonide (STTA) injection. IVTA injection demonstrated greater improvement in visual acuity at 3 months compared with placebo or no treatment, but the benefit was no longer significant at 6 months. Those who received IVTA injection had significantly higher IOP at 3 months and at 6 months. Compared with STTA, IVTA injection demonstrated greater improvement in VA at 3 months, but not at 6 months. IVTA injection demonstrated no difference in IOP at 3 months or at 6 months.
16. Beck RW, Edwards AR, Aiello LP, et al. Diabetic Retinopathy Clinical Research Network (DRCR.net). Three-year follow-up of a randomized trial comparing focal/grid photocoagulation and intravitreal triamcinolone for diabetic macular edema. Arch Ophthalmol 2009;127:245-251 •• Results in a subset of randomized subjects who completed this 3-year follow-up did not indicate a long-term benefit of intravitreal triamcinolone relative to focal/grid photocoagulation in patients with diabetic macular edema. Most eyes receiving 4 mg of triamcinolone, as given in this study, required cataract surgery.
17. Boscia F, Furino C, Dammacco R, et al. Intravitreal triamcinolone acetonide in refractory pseudophakic cystoid macular edema: functional and anatomic results. Eur J Ophthalmol 2005;15:89-95 (Pubitemid 40462735)
18. Benhamou N, Massin P, Haouchine B, et al. Intravitreal triamcinolone for refractory pseudophakic macular edema. Am J Ophthalmol 2003;135:246-249 (Pubitemid 36151814)
19. Koutsandrea C, Moschos MM, Brouzas D, et al. Intraocular triamcinolone acetonide for pseudophakic cystoid macular edema: optical coherence tomography and multifocal electroretinography study. Retina 2007;27:159-164 (Pubitemid 46245641)
20. Jonas JB, Kreissig I, Degenring RF. Intravitreal triamcinolone acetonide for pseudophakic cystoid macular edema. Am J Ophthalmol 2003;136:384-386 (Pubitemid 36904101)
21. Conway MD, Canakis C, Livir-Rallatos C, Peyman GA. Intravitreal triamcinolone acetonide for refractory chronic pseudophakic cystoid macular edema. J Cataract Refract Surg 2003;29:27-33 (Pubitemid 36152276)
22. Karacorlu M, Ozdemir H, Karacorlu S. Intravitreal triamcinolone acetonide for the treatment of chronic pseudophakic cystoid macular oedema. Acta Ophthalmol Scand 2003;81:648-652 (Pubitemid 37527645)
23. Hayreh SS. Prevalent misconceptions about acute retinal vascular occlusive disorders. Prog Retin Eye Res 2005;24:493-519
24. McAllister IL, Vijayasekaran S, Chen SD, Yu DY. Effect of triamcinolone acetonide on vascular endothelial growth factor and occludin levels in branch retinal vein occlusion. Am J Ophthalmol 2009;147:838-846
25. Engler CB, Sander B, Larsen M, et al. Probenecid inhibition of the outward transport of fluorescein across the human blood-retinal barrier. Acta Ophthalmol (Copenh) 1994;72:663-667
26. Cheng KC, Wu WC, Lin CJ. Intravitreal triamcinolone acetonide for patients with macular oedema due to central retinal vein occlusion in Taiwan. Eye 2009;23:849-857
27. Krepler K, Ergun E, Sacu S, et al. Intravitreal triamcinolone acetonide in patients with macular oedema due to central retinal vein occlusion. Acta Ophthalmol Scand 2005;83:71-75 (Pubitemid 40326425)
28. Ip MS, Gottlieb JL, Kahana A, et al. Intravitreal triamcinolone for the treatment of macular edema associated with central retinal vein occlusion. Arch Ophthalmol 2004;122:1131-1136 (Pubitemid 39031127)
29. Ozkiris A, Evereklioglu C, Erkilic K, Dogan H. Intravitreal triamcinolone acetonide for treatment of persistent macular oedema in branch retinal vein occlusion. Eye 2006;20:13-17 (Pubitemid 43090586)
30. Cakir M, Dogan M, Bayraktar Z, et al. Efficacy of intravitreal triamcinolone for the treatment of macular edema secondary to branch retinal vein occlusion in eyes with or without grid laser photocoagulation. Retina 2008;28:465-472 (Pubitemid 351354949)
31. Chen SD, Sundaram V, Lochhead J, Patel CK. Intravitreal triamcinolone for the treatment of ischemic macular edema associated with branch retinal vein occlusion. Am J Ophthalmol 2006;141:876-883
32. Scott IU, Blodi BA, Ip MS, et al. SCORE Study Report 2: interobserver agreement between investigator and reading center classification of retinal vein occlusion type. Ophthalmology 2009;116:756-761
33. Nowak JZ. Age-related macular degeneration (AMD): pathogenesis and therapy. Pharmacol Rep 2006;58:353-363 (Pubitemid 44111070)
34. Jonas JB. Intravitreal triamcinolone acetonide: a change in a paradigm. Ophthalmic Res 2006;38:218-245 (Pubitemid 44213982)
35. Jager RD, Mieler WF, Miller JW. Age-related macular degeneration. N Engl J Med 2008;358:2606-2617
36. Penfold PL, Wen L, Madigan MC, et al. Triamcinolone acetonide modulates permeability and intercellular adhesion molecule-1 (ICAM-1) expression of the ECV304 cell line: implications for macular degeneration. Clin Exp Immunol 2000;121:458-465 (Pubitemid 30671267)
37. Penfold PL, Wen L, Madigan MC, et al. Modulation of permeability and adhesion molecule expression by human choroidal endothelial cells. Invest Ophthalmol Vis Sci 2002;43:3125-3130 (Pubitemid 34977068)
38. Ciulla TA, Chriswell MH, Danis RP, Hill TE. Intravitreal triamcinolone acetonide inhibits choroidal neovascularization in a laser-treated rat model. Arch Ophthalmol 2001;119:399-404
39. Jonas JB, Kreissig I, Degenring RF. Neovascular glaucoma treated by intravitreal triamcinolone acetonide. Acta Ophthalmol 2003;81:540-541 (Pubitemid 37265680)
40. Danis RP, Bingaman DP, Yang Y, Ladd B. Inhibition of preretinal and optic nerve head neovascularization in pigs by intravitreal triamcinolone acetonide. Ophthalmol 1996;103:2099-2104 (Pubitemid 27024631)
41. Penfold PL, Wong JG, Gyory J, Billson FA. Effects of triamcinolone acetonide on microglial morphology and quantitative expression of MHC-II in exudative age-related macular degeneration. Clin Experiment Ophthalmol 2001;29:188-192 (Pubitemid 32618988)
42. Danis RP, Ciulla TA, Pratt LM, Anliker W. Intravitreal triamcinolone acetonide in exudative age-related macular degeneration. Retina 2000;20:244-250 (Pubitemid 30436775)
43. Jonas JB, Kreissig I, Degenring RF. Repeated intravitreal injections of triamcinolone acetonide as treatment of progressive exudative age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 2002;240:873-874 (Pubitemid 36075645)
44. Jonas JB, Akkoyun I, Budde WM, et al. Intravitreal re-injection of triamcinolone for exudative age-related macular degeneration. Arch Ophthalmol 2004;122:218-222 (Pubitemid 38176489)
45. Jonas JB, Kreissig I, Degenring RF. Factors influencing visual acuity after intravitreal triamcinolone acetonide as treatment of exudative age-related macular degeneration. Br J Ophthalmol 2004;88:1557-1562 (Pubitemid 39573597)
46. Jonas JB, Spandau UH, Harder B, et al. Inter-eye difference in exudative age-related macular degeneration with minimally classic or occult subfoveal neovascularization after unilateral intravitreal injection of triamcinolone acetonide. Am J Ophthalmol 2005;139:1073-1079 (Pubitemid 40813320)
47. Ranson NT, Danis RP, Ciulla TA, et al. Intravitreal triamcinolone in subfoveal recurrence of choroidal neovascularization after laser treatment in macular degeneration. Br J Ophthalmol 2002;86:527-529
48. Augustin AJ, Schmidt-Erfurth U. Verteporfin therapy combined with intravitreal triamcinolone in all types of choroidal neovascularization due to age-related macular degeneration. Ophthalmology 2006;113:14-22 (Pubitemid 43021722)
49. Wang K, Wang Y, Gao L, et al. Dexamethasone inhibits leukocyte accumulation and vascular permeability in retina of streptozotocin-induced diabetic rats via reducing vascular endothelial growth factor and intercellular adhesion molecule-1 expression. Biol Pharm Bull 2008;31:1541-1546
50. Edelman JL, Lutz D, Castro MR. Corticosteroids inhibit VEGF-induced vascular leakage in a rabbit model of blood-retinal and blood-aqueous barrier breakdown. Exp Eye Res 2005;80:249-258
51. Heier JS, Boyer DS, Ciulla TA, et al. Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration: year 1 results of the FOCUS Study. Arch Ophthalmol 2006;124:1532-1542 (Pubitemid 44748725)
52. Spaide RF, Sorenson J, Maranan L. Photodynamic therapy with verteporfin combined with intravitreal injection of triamcinolone acetonide for choroidal neo-vascularization. Ophthalmology 2005;112:301-304 (Pubitemid 40202568)
53. Bakri SJ, Couch SM, McCannel CA, Edwards AO. Same-day triple therapy with photodynamic therapy, intravitreal dexamethasone, and bevacizumab in wet age-related macular degeneration. Retina 2009;29:573-578
54. Liggett PE, Colina J, Chaudhry NA, et al. Triple therapy of intravitreal triamcinolone, photodynamic therapy, and pegaptanib sodium for choroidal neovascularization. Am J Ophthalmol 2006;142:1072-1074 (Pubitemid 44853900)
55. Arroyo JG, Michaud N, Jakobiec FA. Choroidal neovascular membranes treated with photodynamic therapy. Arch Ophthalmol 2003;121:898-903 (Pubitemid 36676231)
56. Krammer B. Vascular effects of photodynamic therapy. Anticancer Res 2001;21:4271-4277
57. Rechtman E, Danis RP, Pratt LM, Harris A. Intravitreal triamcinolone with photodynamic therapy for subfoveal choroidal neovascularization in age-related macular degeneration. Br J Ophthalmol 2004;88:344-347 (Pubitemid 38333711)
58. Yip PP, Woo CF, Tang HH, Ho CK. Triple therapy for neovascular age-related macular degeneration using single-session photodynamic therapy combined with intravitreal bevacizumab and triamcinolone. Br J Ophthalmol 2009;93:754-758
59. Rodrigues EB, Maia M, Meyer CH, et al. Vital dyes for chromovitrectomy. Curr Opin Ophthalmol 2007;18:179-187
60. Furino C, Micelli Ferrari T, Boscia F, et al. Triamcinolone-assisted pars plana vitrectomy for proliferative vitreoretinopathy. Retina 2003;23:771-776 (Pubitemid 38040575)
61. Tognetto D, Zenoni S, Sanguinetti G, et al. Staining of the internal limiting membrane with intravitreal triamcinolone acetonide. Retina 2005;25:462-467 (Pubitemid 40791884)
62. Horio N, Horiguchi M, Yamamoto N. Triamcinolone-assisted internal limiting membrane peeling during idiopathic macular hole surgery. Arch Ophthalmol 2005;123:96-99 (Pubitemid 40105436)
63. Triesence™ drug information. Available from: http://www. alconretina.com/ products/triesence.asp
64. Moshfeghi AA, Nugent AK, Nomoto H, et al. Triamcinolone acetonide preparations: impact of crystal size on in vitro behavior. Retina 2009;29:689-698
65. Dyer D, Callanan D, Bochow T, et al. Clinical evaluation of the safety and efficacy of preservative-free triamcinolone (triesence [triamcinolone acetonide injectable suspension] 40 mg/ml) for visualization during pars plana vitrectomy. Retina 2009;29:38-45
66. Bourges JL, Bloquel C, Thomas A, et al. Intraocular implants for extended drug delivery: therapeutic applications. Adv Drug Deliv Rev 2006;58:1182-1202 (Pubitemid 44794429)
67. Lim JI, Wolitz RA, Dowling AH, et al. Visual and anatomic outcomes associated with posterior segment complications after ganciclovir implant procedures in patients with AIDS and cytomegalovirus retinitis. Am J Ophthalmol 1999;127:288-293
68. Driot JY, Novack GD, Rittenhouse KD, et al. Ocular pharmacokinetics of fluocinolone acetonide after Retisert intravitreal implantation in rabbits over a 1-year period. J Ocul Pharmacol Ther 2004;20:269-275
69. Jaffe GJ, Yang CH, Guo H, et al. Safety and pharmacokinetics of an intraocular fluocinolone acetonide sustained delivery device. Invest Ophthalmol Vis Sci 2000;41:3569-3575 (Pubitemid 30774949)
70. Mruthyunjaya P, Khalatbari D, Yang P, et al. Efficacy of low-release-rate fluocinolone acetonide intravitreal implants to treat experimental uveitis. Arch Ophthalmol 2006;124:1012-1018 (Pubitemid 44036324)
71. Jaffe GJ, McCallum RM, Branchaud B, et al. Long-term follow-up results of a pilot trial of a fluocinolone acetonide implant to treat posterior uveitis. Ophthalmology 2005;112:1192-1198 (Pubitemid 40916923)
72. Retisert (fluocinolone acetonide intravitreal implant) formulary kit. Rochester, NY: Bausch & Lomb, May 2005
73. Callanan DG, Jaffe GJ, Martin DF, et al. Treatment of posterior uveitis with a fluocinolone acetonide implant: three-year clinical trial results. Arch Ophthalmol 2008;126:1191-1201 • A 3-year, multicenter, randomized, controlled clinical trial of the 0.59-mg and 2.1-mg fluocinolone acetonide intravitreal implants. Both implant dosages significantly reduced uveitis recurrence and improved or stabilized visual acuity in subjects with noninfectious posterior uveitis. Most subjects required cataract extraction, and a significant proportion required intraocular pressure-lowering surgery.
74. Goldstein DA, Godfrey DG, Hall A, et al. Intraocular pressure in patients with uveitis treated with fluocinolone acetonide implants. Arch Ophthalmol 2007;125:1478-1485 (Pubitemid 350106679)
75. Bausch and Lomb online. Available from: http://www.bausch.com/en-US/ downloads/ecp /pharma/general/retisert- pkginsert.pdf [Last accessed 29 May 2009]
76. Taban M, Lowder CY, Kaiser PK. Outcome of fluocinolone acetonide implant (Retisert™) reimplantation for chronic noninfectious posterior uveitis. Retina 2008;28:1280-1288
77. Galor A, Margolis R, Kaiser PK, Lowder CY. Vitreous band formation and the sustained-release, intravitreal fluocinolone (Retisert) implant. Arch Ophthalmol 2007;125:836-838 (Pubitemid 46919749)
78. Ufret-Vincenty RL, Singh RP, Lowder CY, Kaiser PK. Cytomegalovirus retinitis after fluocinolone acetonide (Retisert) implant. Am J Ophthalmol 2007;143:334-335
79. Clinical trial # NCT00502541. Available from: http://www.clinicaltrial. gov/ct2/ show/NCT00502541?term=fluocinolone+a cetonide&rank=6. [Last accessed on 30 May 2009]
80. Ramchandran RS, Fekrat S, Stinnett SS, Jaffe GJ. Fluocinolone acetonide sustained drug delivery device for chronic central retinal vein occlusion: 12-month results. Am J Ophthalmol 2008;146:285-291 • Prospective, noncomparative, interventional case series of 14 eyes with chronically persistent macular edema associated with CRVO that underwent intraocular implantation of a 3-year fluocinolone acetonide sustained drug delivery system. Visual acuity improved and macular edema decreased in a significant proportion of implanted eyes with chronic, CRVO-associated macular edema. Cataract formation and elevated IOP were the main side effects.
81. Clinical trial # NCT00636493. Available from: http://www.clinicaltrial. gov/ct2/ show/NCT00636493?term=fluocinolone+a cetonide&rank=3. [Last accessed on 30 May 2009]
82. Kane FE, Burdan J, Cutino A, Green KE. Iluvien: a new sustained delivery technology for posterior eye disease. Expert Opin Drug Deliv 2008;5:1039-1046
83. Alimera sciences immediate release. 12-month safety and efficacy results from the first human pharmacokinetic study (PK study) of Iluvien™. Alimera Sciences, Alpharetta, GA, USA: March 12, 2009
84. Clinical trial # NCT00490815. Available from: http://www.clinicaltrial. gov/ct2/ show/NCT00490815?term=fluocinolone+a cetonide&rank=5. [Last accessed on 30 May 2009]
85. Campochiaro PA, Hafiz G, Shah SM, Nguyen QD. FAMOUS Study Group. Pharmacodynamics of Iluvien™, a fluocinolone acetonide sustained delivery vitreous insert. Presented at the Association for Research in Vision and Ophthalmology Meeting, Fort Lauderdale, FL, May 4, 2009. #1676
86. Clinical trial # NCT00605423. ClinicalTrials.gov. Available from: http://www.clinicaltrial.gov/ct2/show/NCT 00605423?term= fluocinolone+acetonide&r ank=14. [Last accessed on 30 May 2009]
87. Clinical trial # NCT00770770. ClinicalTrials.gov. Available from: http://www.clinicaltrial.gov/ct2/show/NCT 00770770?term=Iluvien&rank=1. [Last accessed on 30 May 2009]
88. Hainsworth DP, Pearson PA, Conklin JD, Ashton P. Sustained release intravitreal dexamethasone. J Ocul Pharmacol Ther 1996;12:57-63
89. Jaffe GJ, Pearson PA, Ashton P. Dexamethasone sustained drug delivery implant for the treatment of severe uveitis. Retina 2000;20:402-403
90. Kuppermann BD, Blumenkranz MS, Haller JA, et al. Randomized controlled study of an intravitreous dexamethasone drug delivery system in patients with persistent macular edema. Arch Ophthalmol 2007;125:309-317 •• A 6-month study of patients with persistent macular edema randomized to observation or a single treatment with dexamethasone DDS, 350 or 700 ìg. A single dexamethasone DDS treatment using the higher dose produced statistically significant visual acuity improvement 90 days after treatment and was well tolerated for 180 days.
91. Williams GA, Haller JA, Kuppermann BD, et al. Dexamethasone posterior-segment drug delivery system in the treatment of macular edema resulting from uveitis or Irvine-Gass syndrome. Am J Ophthalmol 2009;147:1048-1054
92. Ozurdex package insert. Irvine, CA: Allergan, Inc., 2009
93. Beeley NR, Stewart JM, Tano R, et al. Development, implantation, in vivo elution, and retrieval of a biocompatible, sustained release subretinal drug delivery system. J Biomed Mater Res A 2006;76:690-698 (Pubitemid 47233477)
94. I-vation sustained drug delivery system. Available from: http://www.surmodics. com/pdf/ophthalmology.pdf. [Last accessed 30 May 2009]
95. Eliott D, Dugel PU, Cantrill HL, et al. I-vation ™ TA: 15-month clinical results of the phase i safety and preliminary efficacy study. Poster presented at the Association for Research in Vision and Ophthalmology, April 28- May 2, 2008, Fort Lauderdale, FL. Abstract 3501
96. Clinical trial # NCT00692614. Available from: http://www.clinicaltrial. gov/ct2/show/ NCT00692614?term=MK0140&rank=1. [Last accessed on 30 May 2009]
97. Stepien KE, Eaton AM, Jaffe GJ, et al. Increased incidence of sterile endophthalmitis after intravitreal triamcinolone acetonide in spring 2006. Retina 2009;29:207-213
98. Clinical trial #NCT00593450. Available from: http://www.clinicaltrial. gov/ct2/show/ NCT00593450?term=CATT&rank=2. [Last accessed on 30 May 2009]